TerminatedNot Applicable

Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Stopped: Business decision to stop the program.

France246 participantsStarted 2017-01-25

Plain-language summary

This observational study will evaluate the safety, efficacy, characteristics of patients, characteristics of physicians and quality of life in patients who are prescribed OZURDEX® as treatment for non-infectious uveitis of the posterior segment of the eye in France.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓Patient with non-infectious uveitis affecting the posterior segment of the eye.

Exclusion criteria

✕Patient not residing in metropolitan France.

What they're measuring

Percentage of Participants with Best Corrected Visual Acuity (BCVA) ≥15 Letters

Timeframe: 2 Months

Trial details

NCT IDNCT02951975

SponsorAllergan

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-11-28

View on ClinicalTrials.gov More Non-infectious Uveitis trials